Acta Med. 2016, 59: 54-58
https://doi.org/10.14712/18059694.2016.54
Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer
References
1. Am J Hum Genet 1999; 64: 218–24.
< YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. https://doi.org/10.1086/302205>
<PubMed>
2. Cancer Res 1977; 37: 646–50.
SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy.
3. Lancet 1997; 350: 485–7.
< YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. https://doi.org/10.1016/S0140-6736(97)02174-0>
4. Biochem Med 2012; 22: 24–38.
< J. Free DNA: new potential analyte in clinical laboratory diagnostics? https://doi.org/10.11613/BM.2012.004>
5. Clin Chem 2009; 55: 1958–66.
< V, Prieto García B, Baltar Martín JM, Ortega Suárez F, Alvarez FV. Cell-free DNA as a noninvasive acute rejection marker in renal transplantation. https://doi.org/10.1373/clinchem.2009.129072>
6. Clin Chem 2008; 54: 1000–7.
< K, Lakkisto P, Pettilä V, et al. Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. https://doi.org/10.1373/clinchem.2007.101030>
7. Clin Chem 2006; 52: 1833–42.
AK, Bhutani M, Kumar S, Mohan A, Guleria R. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool.
8. Int J Cancer 2002; 100: 542–8.
< T, Berger A, Zinzindohoué F, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. https://doi.org/10.1002/ijc.10526>
9. Pancreas 1998; 17: 89–97.
< MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. https://doi.org/10.1097/00006676-199807000-00012>
10. Clin Chim Acta 2008; 387: 55–8.
< N, Kamataki A, Yamaki J, Homma Y. Characterization of circulating DNA in healthy human plasma. https://doi.org/10.1016/j.cca.2007.09.001>
11. Clin Chem Lab Med 2010; 48: 1665–8.
< E, Montagnana M, Minicozzi AM, et al. Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers. https://doi.org/10.1515/CCLM.2010.301>
12. Clin Chem 2015; 61: 1299–304.
< MB, Freydina DV, Leung M, et al. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. https://doi.org/10.1373/clinchem.2015.242453>
13. Cancer Epidemiol Biomarkers Prev 1994; 3: 67–71.
GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood.
14. Gastroenterology 1997; 112: 1114–20.
< P, Lefort F, Vasioukhin V, et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. https://doi.org/10.1016/S0016-5085(97)70121-5>
15. N Engl J Med 2013; 368: 1199–209.
< SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. https://doi.org/10.1056/NEJMoa1213261>
16. Biochem Biophys Res Commun 2004; 325: 784–91.
< I, Scibetta AG, Migliavacca M, et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. https://doi.org/10.1016/j.bbrc.2004.10.111>
17. Clin Cancer Res 2010; 16: 790–9.
< SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. https://doi.org/10.1158/1078-0432.CCR-09-2446>
18. Nature 2012; 486: 537–40.
< LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. https://doi.org/10.1038/nature11219>
<PubMed>
19. Mol Oncol 2014; 8: 927–41.
< F, El Messaoudi S, Pang D, Dritschilo A, Thierry AR. Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. https://doi.org/10.1016/j.molonc.2014.02.005>
<PubMed>
20. PLoS One 2011; 6: e23418.
< F, Robert B, Arnau Peyrotte E, et al. High fragmentation characterizes tumour-derived circulating DNA. https://doi.org/10.1371/journal.pone.0023418>
<PubMed>
21. Ann N Y Acad Sci 2008; 1137: 135–9.
< C, Weickmann S, Schmidt B, Fleischhacker M. An improved method for the isolation of free-circulating plasma DNA and cell-free DNA from other body fluids. https://doi.org/10.1196/annals.1448.035>
22. Anal Chim Acta 2009; 652: 231–3.
< KJ, Thain L, Docker PT, et al. The use of carrier RNA to enhance DNA extraction from microfluidic-based silica monoliths. https://doi.org/10.1016/j.aca.2009.03.038>
23. J Forensic Sci 2006; 51: 1055–61.
< R, Hardy R, Anderson VJ, Sanchez NA, Buoncristiani MR. Optimization of DNA extraction from low-yield and degraded samples using the BioRobot EZ1 and BioRobot M48. https://doi.org/10.1111/j.1556-4029.2006.00204.x>
24. J Clin Microbiol 1994; 32: 2593–7.
RC, Matsui SM, Greenberg HB. Rapid and sensitive method for detection of hepatitis C virus RNA by using silica particles.
25. Trends Biochem Sci 1996; 21: 224–5.
< PN. Carriers for precipitating nucleic acids. https://doi.org/10.1016/S0968-0004(96)30031-5>
26. J Natl Cancer Inst 2000; 92: 918–23.
< MS, Benko FA, Borys DJ, Khan A, McGarrity TJ, Gocke CD. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. https://doi.org/10.1093/jnci/92.11.918>
27. Ann N Y Acad Sci 2000; 906: 29–30.
< BM, McManus RO, Daly JS, et al. Serum mutant K-ras in the colorectal adenoma-to-carcinoma sequence. Implications for diagnosis, postoperative follow-up, and early detection of recurrent disease. https://doi.org/10.1111/j.1749-6632.2000.tb06586.x>
28. Br J Cancer 2001; 85: 692–6.
< HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. https://doi.org/10.1054/bjoc.2001.1964>
<PubMed>
29. Lancet Oncol 2010; 11: 753–62.
< W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. https://doi.org/10.1016/S1470-2045(10)70130-3>